950 — Lee's Pharmaceutical Holdings Income Statement
0.000.00%
- HK$783.15m
- HK$690.71m
- HK$1.40bn
- 94
- 91
- 89
- 100
Annual income statement for Lee's Pharmaceutical Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,217 | 1,266 | 1,233 | 1,053 | 1,400 |
Cost of Revenue | |||||
Gross Profit | 781 | 806 | 771 | 551 | 753 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,065 | -712 | 1,157 | 1,009 | 1,287 |
Operating Profit | 152 | 1,979 | 76.6 | 43.6 | 113 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 134 | 1,969 | 67.9 | 30.8 | 98.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 78.5 | 1,960 | 45.8 | 19.9 | 68.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 129 | 1,987 | 51.3 | 16.7 | 93.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 129 | 1,987 | 51.3 | 16.7 | 93.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.25 | 1.07 | 0.09 | 0.019 | 0.193 |
Dividends per Share |